Methamphetamine use disorder (MUD) is a common neuropsychiatric disease that is associated with several short-term and long-term complications. These include cognitive deficits, memory impairments, and psychosis. There is presently no FDA-approved drug treatment for MUD. Dr. Cadet’s laboratory uses basic science approaches to develop better pharmacological therapy for these patients.
Learning Objectives:
- To learn basic aspects of methamphetamine
- Neurochemical effects
- Behavioral effects
- To learn the varied clinical presentations of methamphetamine use
- Acute effects
- Chronic effects
- To learn the DSM criteria of methamphetamine use disorder
- Compulsive use
- Loss of control
- Use despite adverse consequences
- To learn about animal models of methamphetamine use disorder in rats
- Behavioral effects of punishment (adverse consequences)
- Biochemical consequences
- Epigenetic consequences
Attend Virtually or In-Person
Friday, June 23rd
Earn 1 CME/CEU
Space is limited for on-site attendees. Please RSVP by June 18th if you plan to attend on-site.
This event has already occurred, click here to watch the presentation on demand.
See what licenses are covered.
Jean Lud Cadet, M.D. is presently a NIH Tenured Senior Investigator and the Chief of the Molecular Neuropsychiatry Research Branch and of the Molecular Neuropsychiatry Section at the National Institutes of Health/National Institute on Drug Abuse (NIDA) intramural research program (IRP). Dr. Cadet attended medical school at the Columbia University College of Physicians and Surgeons. He subsequently did psychiatry residency at the Department of Psychiatry at Columbia University and Neurology Residency at Mount Sinai Hospital in New York City. He did a post-residency fellowship at the NIMH and was an assistant professor of Neurology and Psychiatry at Columbia University before coming to NIDA IRP. Dr. Cadet has co-authored more than 500 papers, reviews, and book chapters on the molecular neurobiology of substance use disorders, cognitive aspects of cocaine and marijuana use disorders, clinical neurobiology of schizophrenia and tardive dyskinesia, as well as on mechanisms involved in models of neurodegeneration including Parkinsonism.
His work is very highly cited, with 29,691 citations and he presently has a H-index of 92. Presently, his laboratory studies the epigenetic mechanisms that potentially regulate stimulant and oxycodone-induced changes in the expression of genes in specific neuronal cells and brain regions within the reward pathways. Dr. Cadet has served on the Editorial Board of Synapse, is presently on the Editorial Board of Neurotoxicity Research, Current Neuropharmacology, International Journal of Neuropsychopharmacology, Scientific reports, and the Journal of Addictive Diseases. He is a reviewing editor for Scientific Reports and associate editor of Frontier in Public Health. Dr. Cadet is also a member of the Society for Neuroscience, ASPET, National Medical Association, Black in Neuro, Neurotoxicity Society, AMHE (Association des Medecins Haitiens a L’ Etranger), Society of Haitian Neuroscientists (SHN). He has received several awards including the NIH Director’s Award, visiting professorships including the Grass Foundation Lectureship, The Associated Medical Schools of NY for dedication and service to the promotion of Science and Health among minority youth, and the NIH Harvey J. Bullock Award.
Joint Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Galen Mental Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.